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Background. Second-line antiretroviral therapy (ART) based on ritonavir-boosted protease inhibitors (bPIs) represents the only 
available option after first-line failure for the majority of individuals living with human immunodeficiency virus (HIV) worldwide. 
Maximizing their effectiveness is imperative.
Methods. This cohort study was nested within the French National Agency for AIDS and Viral Hepatitis Research (ANRS) 
12249 Treatment as Prevention (TasP) cluster-randomized trial in rural KwaZulu-Natal, South Africa. We prospectively investigated 
risk factors for virological failure (VF) of bPI-based ART in the combined study arms. VF was defined by a plasma viral load >1000 
copies/mL ≥6 months after initiating bPI-based ART. Cumulative incidence of VF was estimated and competing risk regression was 
used to derive the subdistribution hazard ratio (SHR) of the associations between VF and patient clinical and demographic factors, 
taking into account death and loss to follow-up.
Results. One hundred one participants contributed 178.7 person-years of follow-up. Sixty-five percent were female; the median 
age was 37.4 years. Second-line ART regimens were based on ritonavir-boosted lopinavir, combined with zidovudine or tenofovir 
plus lamivudine or emtricitabine. The incidence of VF on second-line ART was 12.9 per 100 person-years (n = 23), and prevalence 
of VF at censoring was 17.8%. Thirteen of these 23 (56.5%) virologic failures resuppressed after a median of 8.0 months (interquartile 
range, 2.8–16.8 months) in this setting where viral load monitoring was available. Tuberculosis treatment was associated with VF 
(SHR, 11.50 [95% confidence interval, 3.92–33.74]; P < .001).
Conclusions. Second-line VF was frequent in this setting. Resuppression occurred in more than half of failures, highlighting the 
value of viral load monitoring of second-line ART. Tuberculosis was associated with VF; therefore, novel approaches to optimize the 
effectiveness of PI-based ART in high-tuberculosis-burden settings are needed.
Clinical Trials Registration. NCT01509508.
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Despite clinical and public health gains following antiretro-
viral therapy (ART) rollout, treatment failure of first-line 
nonnucleoside reverse transcriptase inhibitor (NNRTI)–
based ART is common [1–4], with up to 3 million human 
immunodeficiency virus (HIV)–infected patients estimated 
to receive second-line, boosted protease inhibitor (bPI)–based 
ART by 2020 [5]. Treatment failure on second-line ART is a 
major concern given poor, if any, access to further regimens in 
high-burden settings.
Data from observational studies of second-line bPI-based 
ART treatment outcomes in sub-Saharan Africa suggest a 
14%–32% prevalence of virological failure (VF) [6–12], with 
randomized trials from comparable settings reporting lower 
prevalence of VF at 17%–19% at 48 weeks and longer durations 
of follow-up [13–16]. These studies were largely conducted in 
urban or periurban areas. Although associations have been 
reported between second-line VF and poor adherence [6, 
8, 10, 17, 18] and delayed switch [7, 9], socioeconomic and 
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demographic factors such as education level, employment, and 
data on household members have not been studied together. 
Furthermore, the potentially critical association between con-
comitant tuberculosis (TB) [17] and second-line bPI failure is 
inconclusive.
Previously published cohort studies have used a Kaplan-
Meier survival analysis and standard Cox regression models 
that can result in inflated estimates due to competing events. 
Competing risk regression analysis overcomes this limitation 
by accounting for events, such as death, that preclude the sub-
ject from experiencing the study outcome. This is particularly 
important in sub-Saharan Africa where mortality remains sig-
nificant following ART initiation due to advanced disease stage 
as well as loss to follow-up [19]. Here we have applied compet-
ing risk methods to comprehensively and prospectively investi-
gate risk factors for VF of bPI-based second-line ART in a rural 
population of South Africa. In this setting ART was readily 
available and follow-up optimum according to local standards, 
including real-time viral load monitoring.
MATERIALS AND METHODS
Study Setting and Study Design
This cohort study was nested within the French National 
Agency for AIDS and Viral Hepatitis Research (ANRS) 12249 
Treatment as Prevention (TasP) trial (ClinicalTrials.gov iden-
tifier: NCT01509508), an ongoing cluster-randomized trial 
evaluating the impact of immediate vs deferred ART initiation 
(according to South African guidelines) on HIV incidence [20] 
(see Supplementary Materials). The trial started recruiting in 
March 2012 in Hlabisa subdistrict, Umkhanyakude district, 
Northern KwaZulu-Natal, where the antenatal prevalence of 
HIV is 44%, one of the highest in South Africa [21, 22]. This 
rural setting is also one of the poorest districts in South Africa 
with very high unemployment rates.
This analysis is based on the treatment outcomes documented 
prospectively in the subgroup of patients on second-line bPI-
based treatment within the TasP trial. Participants from all 
clusters irrespective of trial arm were included in this cohort. 
Participants were aged >15  years, resident in Hlabisa subdis-
trict, and included from the date of initiation of second-line 
treatment till the earliest of the date last seen in clinic, death, 
or loss to follow-up. No participants initiating bPI ART after 
May 2015 were included to allow at least 6 months’ follow-up 
for the primary outcome to occur. The participants’ outcomes 
were recorded until November 2015.
Outcome and Prespecified Explanatory Variables
The primary outcome was VF defined as a VL >1000 copies/mL 
on at least 1 occasion ≥6 months after commencing second-line 
treatment. Any death occurring during the trial period was 
recorded and follow-up time was censored at the date of death. 
Loss to follow-up was defined as ≥3 consecutive missed clinic 
appointments. Follow-up time was censored at the last clinic 
visit. For all the other participants who remained in the trial 
with virological suppression (VL < 1000 copies/mL), follow-up 
was censored as the latest of either the date of the last laboratory 
test or last clinic visit.
Clinic Procedures and Laboratory Methods
At presentation to the trial clinics, all consenting HIV-infected 
participants were asked to complete the study questionnaires 
and underwent clinical examination by trial nurses. CD4 count 
was measured in TasP clinics using a commercial point-of-
care CD4 test (Alere PIMA device tool, Alere Inc, Waltham, 
Massachusetts). VL was measured using The Abbott m2000 
RealTime System with HIV type 1 (HIV-1) VL determina-
tion from human plasma of HIV-1–infected individuals in 
the range of 40–10 000 000 copies/mL (Abbott Molecular Inc, 
Des Plaines, Illinois). The viral load assay was CE (Conformité 
Européene) marked and performed at the Africa Centre lab-
oratory; the laboratory participated in Quality Control for 
Molecular Diagnostics (QCMD) for VL quality assurance 
testing. Both CD4 and viral load were measured at baseline, 
and at months 3 and 6 after ART initiation and every 6 months 
thereafter. Full-genome deep sequencing was performed after 
2 consecutive VL measurements >1000 copies/mL at least 
6 months apart following second-line VF, as per adapted pro-
tocol from Gall et  al [23]. In brief, 4 overlapping fragments, 
spanning approximately 9 kb of the HIV genome, were ampli-
fied and purified as per adapted protocol from Gall et al [23]. 
The library preparation was done on equimolar pooled ampli-
cons, using the Nextera XT Library preparation kit, followed by 
sequencing on the Illumina MiSeq platform. Next-generation 
sequencing (NGS) data were analyzed on Geneious software 
and a threshold of 2% was used for minority variants detec-
tion, with a minimum coverage of 1000 reads. In the case of 
a single VL >1000 copies/mL, Sanger sequencing was done 
following Manasa et  al’s protocol [24]. The external quality 
assurance for Sanger sequencing was with QCMD. Drug resist-
ance mutations were identified according to the Stanford HIV 
Drug Resistance Database (http://hivdb.stanford.edu/) [25]. 
We reported mutations where they were detected above 2% 
frequency. Safety monitoring blood samples were also taken as 
per protocol [20].
Statistical Analysis
Participant characteristics were reported using frequency and 
percentage for categorical variables and median and interquar-
tile range (IQR) for continuous variables. The incidence of sec-
ond-line failure per 100 person-years was estimated with its 
95% confidence interval (CI).
We estimated the cumulative incidence function of VF on 
second-line treatment, taking into account death and loss to 
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follow-up as competing risks. Competing risk regression was 
used to estimate the subdistribution hazard ratio (SHR) of the 
associations between VF and participant clinical and demo-
graphic factors, accounting for the competing risks of death and 
loss to follow-up, according to the model of Fine and Gray [26]. 
In the final multivariable model, mutually adjusted estimates of 
the SHRs were determined by including those factors with evi-
dence of an association in the univariable analysis and a P value 
of <.1. Although age and sex were not significantly associated 
with VF in the univariable analysis, they were kept in the final 
model as they were a priori specified confounders. Analysis was 
done using Stata software version 13.
Ethical Committee Approval
Ethics approval was granted by the Biomedical Research Ethics 
Committee of the University of KwaZulu-Natal (BFC 104/11) 
and the Medicines Control Council of South Africa. The study 
was also authorized by the KwaZulu-Natal Department of 
Health in South Africa. Written informed consent was obtained 
from all participants.
RESULTS
One hundred one participants were included in this analysis. 
Sixteen (15.8%) individuals were already on second-line treat-
ment at enrollment into the trial for a median of 2.7 years (IQR, 
1.1–3.9 years). Three of these participants had VF at the base-
line clinic visit. Seven (6.9%) participants had not initiated ART 
at enrollment into the trial. The remaining 78 (77.2%) were on 
first-line NNRTI-based ART for a median duration of 4.9 years 
(IQR, 3.2–6.7  years) at the time of enrollment; 41 (52.6%) of 
these had VF at the baseline clinic visit in the TasP trial, neces-
sitating a switch to bPI along with 2 nucleoside reverse tran-
scriptase inhibitors (NRTIs). Median duration on bPI for the 85 
patients was 0.6 years (IQR, 0.3–0.9 years).
The majority of participants were female (65.4%) and the 
median age at initiation of second-line treatment was 37.4 years 
(IQR, 31.6–45.3 years). There was a high level of unemployment 
(91.9%) in this cohort of participants residing in a rural setting 
(Table 1). Thirteen individuals (12.9%) were diagnosed with TB 
during the study period.
Virological Failure and Associated Risk Factors
The 101 participants contributed 178.7 person-years of fol-
low-up to the analysis. The overall incidence of VF on sec-
ond-line ART was 12.9 per 100 person-years. At administrative 
censoring, 76 participants were alive and in care, 1 had died, 
and 1 was lost to follow-up before any VF was documented, and 
23 participants had VF at least 6 months after initiating bPI sec-
ond-line ART (Supplementary Figure 1). Following intensifica-
tion of adherence counseling, 13 of the 23 participants (56.5%), 
including the 3 patients with bPI VF at the baseline clinic visit, 
Table 1. Demographic and Clinical Characteristics of Study Participants
Characteristic No. (%)
Sex (n = 101)
 Female 66 (65.4)
Age at initiating bPI-based ART, y, median (IQR) (n = 101) 37.4 (31.6–45.3)
Relationship status (n = 100)
 Single 76 (76.0)
 Married 17 (17.0)
 Widowed 7 (7.0)
Employed (n = 87)
 Yes 7 (8.1)
Education level (n = 101)
 Primary or less 46 (45.5)
 Some secondary 30 (29.7)
 Completed secondary 25 (24.8)
Household asset ownership index score (n = 100)
 Low 37 (37.0)
 Medium 52 (52.0)
 High 11 (11.0)
Other HIV-positive household member (n = 101)
 Yes 68 (67.3)
Distance to national highway, km, median (IQR) (n = 101) 2.5 (1.4–5.6)
Distance to clinic, km, median (IQR) (n = 101) 1.2 (0.8–1.9)
Clinical characteristics
 Duration of HIV diagnosis, y, median (IQR) (n = 95) 5.1 (2.7–7.6)
 Duration on NNRTI-based first-line ART, y, median (IQR) 
(n = 101)
4.6 (2.2–6.4)
 Duration on bPI-based second-line ART, y, median (IQR) 
(n = 101)
2.0 (1.4–2.5)
 On bPI before recruitment to TasP (n = 101)
  Yes 16 (15.8)
 CD4 within 6 mo prior to switch to bPI, cells/mm3, 
median (IQR) (n = 31)
180 (107–343)
 Viral load within 6 mo of switch to bPI, copies/mL (n = 61)
  <1000 18 (29.5)
  >1000 43 (70.5)
 Nadir CD4 count prior to first-line ART, cells/mm3, 
median (IQR) (n = 94)
95.5 (17.0–191.0)
 Tuberculosis treatment within 6 mo of PI failure  
(n = 94)
5 (5.3)
 No. of clinic visits/y, median (IQR) (n = 101) 12.7 (10.4–14.0)
 WHO stage (n = 90) at cohort baseline
  1 47 (53.2)
  2 18 (20.0)
  3 23 (25.6)
  4 2 (2.2)
 Median pill count, % (n = 92)
  0–96 25 (27.2)
  ≥97 67 (72.8)
 First-line regimen
  ZDV/d4T + 3TC/FTC + NVP/EFV 54 (53.5)
  TDF + 3TC/FTC + NVP/EFV 47 (46.5)
 Second-line regimen
  ZDV/TDF + 3TC/FTC + LPV/r 101 (100.0)
Data are presented as No. (%) unless otherwise indicated.
Abbreviations: 3TC, lamivudine; ART, antiretroviral therapy; bPI, ritonavir-boosted protease 
inhibitor; d4T, stavudine; EFV, efavirenz; FTC, emtricitabine; HIV, human immunodefi-
ciency virus; IQR, interquartile range; LPV/r, lopinavir/ritonavir; NNRTI, nonnucleoside 
reverse transcriptase inhibitor; NVP, nevirapine; TasP, treatment as prevention; TDF, tenofo-
vir disoproxil fumarate; WHO, World Health Organization; ZDV, zidovudine. 
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resuppressed with a VL <1000 copies/mL after a median of 
8.0 months (IQR, 2.8–16.8 months) (Supplementary Figure 2). 
Eight of these 13 participants subsequently rebounded with a 
VL >1000 copies/mL. The prevalence of VF in patients alive and 
on bPI ART at the time of administrative censoring was 17.8% 
(18/101).
In the univariable analysis, second-line VF was associated 
with concomitant TB treatment within 6  months of failure 
(SHR, 15.9 [95% CI, 6.2–40.6]; P < .0001) and a lower level of 
adherence (median pill count <97%) (SHR, 2.4 [95% CI, 1.0–
5.7]; P =  .04). In the multivariable analysis, the association of 
TB treatment with VF on bPI second-line treatment remained 
(SHR, 11.5 [95% CI, 3.9–33.7]; P <  .001), whereas the associ-
ation with median pill count was no longer present (Table 2).
Thirteen participants were diagnosed with TB and received 
antituberculosis treatment during the study observation period; 
4 of them were treated within 6 months of VF; 1 participant, 
within 6  months of censoring, did not experience VF; the 
remaining 8 participants were diagnosed and treated for TB at 
time points distant from their study exit and did not exhibit VF 
after initiation of antituberculosis treatment.
Drug Resistance
Genotypes were available at first-line NNRTI ART failure in 
9 participants and at bPI ART failure in 6 participants of the 
23 with VF failure of second-line ART (Table 3). The reasons 
for missing genotypes were as follows: 4 patients receiving 
care in Department of Health clinics and therefore no sam-
ple was available; resuppression in 10 patients and therefore 
no viremic confirmatory sample available for genotyping; and 
no confirmatory sample in 2.  Three of 5 patients exposed to 
tenofovir in their first-line regimen developed high-level ten-
ofovir resistance with the K65R mutation, and 2 had accessory 
tenofovir mutations A62V, V75I, or F77L in the reverse tran-
scriptase gene. In one of these individuals, K65R was detected 
only by NGS (at 12% frequency; Table 3). All first-line failures 
had major NNRTI resistance and 5 of 9 had high-level lami-
vudine/emtricitabine resistance (M184V/I). An additional drug 
resistance–associated variant (at <20% frequency) conferring 
NNRTI resistance was detected in patient 6 (K103N at 12%). 
NGS did not detect minority variants in the protease gene in 
any of the 9 patients with second-line failure.
At second-line bPI ART failure, only 1 of 8 (12.5%) partici-
pants had acquired major PI mutations: M46I, I54V, L76V, and 
V82A. This individual received rifampicin containing TB treat-
ment started at the same time as double-dose bPI.
DISCUSSION
We determined the incidence rate for VF on second-line ART 
and associated risk factors in rural KwaZulu-Natal within the 
TasP trial. The incidence rate of VF was 12.9 per 100 per-
son-years (95% CI, 8.6–19.4), and prevalence was 17.8% at 
the end of the observation period. A meta-analysis of studies 
conducted in resource-limited settings reported a pooled prev-
alence of VF of 23.1% (range, 11.4%–39.9%) after 12 months of 
treatment with bPI ART [6], although our prevalence estimate 
was based on a follow-up period of <1 year in those initiated 
on second-line ART within TasP. More recent randomized trials 
reported a lower prevalence of VF, between 14% and 19% at 
48 and 96 weeks of treatment [13–15, 27]. However, the lower 
prevalence within trials may not be generalizable to the “real 
world” because trial participants are closely monitored.
There are considerable differences between studies in the 
definition of VF (from VL >50 to >1000 copies/mL), and 
guidelines are not clear on a definition of second-line failure 
that should trigger a switch of treatment regimen. We there-
fore chose a pragmatic definition of a single VL >1000 copies/
mL, particularly as the follow-up time was relatively short for 
patients in TasP who switched to second-line ART within the 
trial. We found that many patients with VF on bPI ART resup-
pressed to VL <1000 copies/mL following a period of intense 
adherence counseling. This phenomenon has been reported in 
patients treated with first-line ART in both South Africa [28] 
and other parts of sub-Saharan Africa [29], and demonstrates 
that the efficacy of second-line treatment could be optimized if 
regular VL monitoring is widely available, adding to the impe-
tus for development of point-of-care VL testing in tandem with 
effective adherence counseling.
The association between TB treatment and VF of NNRTI-
based first-line ART has previously been reported [17]. Here we 
found evidence of an association between TB treatment and VF 
of second-line treatment. Our study design did not allow us to 
infer causality between TB treatment and VF, as some patients 
were never virologically suppressed even before the rifampicin 
treatment. TB disease itself could be a marker of virological and 
clinical failure; indeed, the 2010 World Health Organization 
(WHO) clinical criteria for treatment failure include a new 
diagnosis of TB [30]. In patients failing during the rifampicin 
treatment, the mechanism leading to VF may be due to drug 
interactions between PIs and rifampicin. Rifampicin, a potent 
cytochrome P450 3A4 inducer, significantly reduces the serum 
levels of PIs, and concurrent use can lead to VF [31, 32]. To 
compensate for this phenomenon, double-dosed bPI has been 
proposed—from twice-daily 400 mg/100 mg to 800 mg/200 mg 
of lopinavir/ritonavir, as is in this clinical setting [33]. However, 
the success of such a strategy may be limited by intolerance to 
the higher doses of PIs [34–36]. Nonadherence to treatment may 
also contribute to failure as the inherent polypharmacy required 
to treat both conditions may be a challenge for patients.
Poor adherence has been shown to be associated with VF in 
other studies [6, 8, 10, 17, 18]; however, we found no association 
between adherence measured by pill count and VF. This might in 
part be due to the fact that adherence was high in this trial context, 
although announced pill count is susceptible to pill dumping by 
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Table 2. Subdistribution Hazard Ratios (SHRs) of Clinical and Demographic Characteristics and Association With Virological Failure on Second-line 
Ritonavir-Boosted Protease Inhibitor–Based Treatment: Univariable Analysis Followed by Multivariable Model of Mutually Adjusted SHRs
Characteristic
Univariable Model Multivariable Model
Events/Follow-up Timea Rate (95% CI)b SHR (95% CI) P Value SHR (95% CI) P Value
Sex
 Female 15/1.29 11.59 (6.99–19.22) 1 .90 1 .79
 Male 8/0.51 15.72 (7.87-31.45) 1.06 (.45–2.49) 0.85 (.18–1.64)
Age at initiating bPI-based ART, y
 16–35 11/0.78 14.18 (7.85–25.61) 1 .61 1 .98
 ≥35 12/1.03 11.68 (6.63–20.56) 0.81 (.36–1.82) 1.02 (.33–3.04)
Relationship status
 Single 18/1.34 13.48 (8.49–21.39) 1 .55
 Married 3/0.34 8.68 (2.80–26.90) 0.72 (.19–2.67)
 Widowed 2/0.10 20.20 (5.05–80.75) 1.72 (.53–5.59)
Education level
 Primary or less 11/0.84 13.13 (7.27–23.71) 1 .93
 Some secondary 6/0.43 13.85 (6.22–30.83) 1.16 (.47–2.84)
 Completed secondary 6/0.53 11.28 (5.07–25.10) 1.18 (.41–3.38)
Employed
 No 16/1.29 12.41 (7.60–20.26) 1 .87
 Yes 1/0.09 10.65 (1.50–75.62) 0.86 (.16–4.79)
Household asset ownership index score
 Low 7/0.69 10.20 (4.86–21.39) 1 .87
 Medium 14/0.92 15.18 (8.99–25.63) 1.14 (.44–2.93)
 High 2/0.17 11.55 (2.89–46.20) 1.42 (.37–5.47)
Other HIV-positive household member
 No 8/0.56 14.29 (7.14–28.57) 1 .70
 Yes 15/1.24 12.07 (7.27–20.12) 1.17 (.52–2.61)
Distance to national highway, km
 <2 14/0.69 20.35 (12.05–34.36) 1 .16
 2–16 9/1.12 8.07 (4.20–15.51) 0.54 (.23–1.27)
Distance to clinic, km
 <1 10/0.76 13.23 (7.12–24.58) 1
 1–2 8/0.61 13.11 (6.55–26.20) 1.78 (.70–4.52)
 2–4 5/0.44 11.45 (4.77–27.52) 0.81 (.27–2.41) .34
Clinical characteristics
 Nadir CD4 prior to first-line ART, cells/mm3
  <100 8/0.48 16.78 (8.39–33.56) 1 .37
  ≥100 10/0.93 10.72 (5.77–19.92) 0.66 (.26–1.66)
 Tuberculosis treatment within 6 mo of PI failure
  No 17/1.62 10.47 (6.51–16.84) 1 <.0001c 1 <.001c
  Yes 4/0.03 116.23 (43.62–309.68) 15.86 (6.21–40.56) 11.50 (3.92–33.74)
 No. of visits per year
  0–11 17/0.91 18.76 (11.67–30.18) 1 .75
  12–22 6/0.90 6.69 (3.01–14.89) 0.85 (.30–2.34)
 WHO stage
  1 7/0.80 8.79 (4.19–18.44) 1 .26
  2 7/0.26 27.12 (12.93–56.89) 2.03 (.86–4.81)
  3/4 7/0.50 13.94 (6.64–29.24) 1.37 (.42–4.51)
 Median pill count, %
  ≥97 12/1.30 27.14 (14.12–52.16) 1 .04c 1 .28
  0–96 9/0.33 9.20 (5.23–16.20) 2.41 (1.02–5.65) 1.83 (0.61–5.50)
 Duration between HIV diagnosis and baseline. y
  0–3 8/0.66 12.21 (6.11–24.42) 1 .87
  4–7 8/0.64 12.41 (6.21–24.82) 0.80 (.31–2.05)
  8–20 5/0.36 13.75 (5.73–33.05) 1.01 (.32–3.17)
 On PI before recruitment to TasP
  No 16/1.31 12.22 (7.49–19.95) 1 .13
  Yes 7/0.49 14.17 (6.76–29.73) 1.97 (.81–4.75)
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participants and therefore not be a particularly good marker for 
adherence: indeed, 88% of participants on first-line NNRTI ART 
had an overall adherence of ≥95% at 6 months [37].
We found multiple major NRTI and NNRTI mutations at 
first-line failure in the participants who had genotype testing 
(9 participants), consistent with data from resource-limited 
settings [2, 38]. Though numbers were small, NGS increased 
detection of significant tenofovir resistance (K65R mutation) by 
around 50%, consistent with previous NGS studies in this set-
ting [39]. We found acquired major protease mutations in only 
1 (11%) failing bPI ART, consistent with other data from South 
Africa [8, 18, 40–42]. NGS did not increase the detection rate of 
Table 3. Resistance Mutations Identified by Next-Generation Sequencing
Participant ID First-line Regimen
Second-line 
Regimen
Duration on 
bPI, y Time-point PI Mutations NRTI Mutations NNRTI Mutations
1 d4T, 3TC, EFV TDF, 3TC, LPV/r 2.0 First-line failure — M184V K103N, P225H, 
K238T
Second-line failure — — P225H10%, K238T8%
2 TDF, FTC, EFV ZDV, 3TC, LPV/r 2.3 First-line failure — — —
Second-line failure — — —
3 TDF, 3TC, EFV TDF, 3TC, LPV/r 1.1 First-line failure — A62V, K65R, V75I, Y115F E138Q, G190E
Second-line failure* — — —
4 d4T, 3TC, NVP
d4T, 3TC, EFV
TDF, 3TC, LPV/r 1.7 First-line failure — M184V K103N, P255H
Second-line failure — — —
5 d4T, 3TC, EFV TDF, 3TC, LPV/r 1.9 First-line failure — T69N, K70N V106M, E138G6%, 
G190A, F227L
Second-line failure — —
6 TDF, 3TC, EFV ZDV, 3TC, LPV/r 2.1 First-line failure — — K103N12%, V106M, 
G190A
Second-line failure —
7 d4T, 3TC, EFV
ZDV, 3TC, EFV
TDF, 3TC, LPV/r 1.6 First-line failure — M41L, L74I, V75L, M184V, 
T215Y
V106M, V179D
Second-line failure — —
8 d4T, 3TC, EFV
TDF, 3TC, EFV
ZDV, 3TC, LPV/r 2.0 First-line failure — M41L, A62V, K65R, K70T2%, 
V75I, M184V
K103N, V106M, 
E138G, F227L6%
Second-line failure M46I, I54V, L76V, 
V82A
T215Y E138G5%
9 d4T, 3TC, NVP
TDF, FTC, EFV
TDF, 3TC, LPV/r 1.5 First-line failure — K65R12%, M184V K103N, Y188L/F15%, 
K238T
Second-line failure —
First-line failure time-point indicates mutations present at first-line NNRTI virological failure. Second-line failure time-point indicates mutations acquired or lost where there are second-line 
bPI failure sequencing data available. These are presented in boldface type where they are newly acquired and where a mutation is lost. Minority variants detected between 2% and 20% 
are reported in italic type with their respective frequencies in subscript. Sequences with an asterisk (*) indicate population sequencing data derived by Sanger methodology. Dash (—) 
indicates no mutations. 
Abbreviations: 3TC, lamivudine; bPI, ritonavir-boosted protease inhibitor; d4T, stavudine; EFV, efavirenz; FTC, emtricitabine; ID, Identity Document; LPV/r, lopinavir/ritonavir; NNRTI, nonnu-
cleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; NVP, nevirapine; PI, protease inhibitor; TDF, tenofovir disoproxil fumarate; ZDV, zidovudine.
Characteristic
Univariable Model Multivariable Model
Events/Follow-up Timea Rate (95% CI)b SHR (95% CI) P Value SHR (95% CI) P Value
 Duration on first-line regimen, y
  <3 7/0.61 11.50 (5.48–24.12) 1 .35
  3–5 7/0.73 9.58 (4.67–20.09) 0.69 (.24–1.94)
  6–12 9/0.46 19.42 (10.11–37.33) 1.38 (.50–3.84)
 Duration on second-line regimen, y
  <2 8/0.56 14.18 (7.09–28.36) 1 .72
  2–3 9/0.70 12.87 (6.70–24.73) 0.99 (.38–2.56)
  3–10 6/0.54 11.12 (5.00–24.75) 1.47 (.49–4.40)
Data are presented as No. (%) unless otherwise indicated.
Abbreviations: ART, antiretroviral therapy; bPI, ritonavir-boosted protease inhibitor; CI, confidence interval; HIV, human immunodeficiency virus; PI, protease inhibitor; SHR, subdistribution 
hazard ratio; TasP, treatment as prevention; WHO, World Health Organization.
aFollow-up time in 100 person-years.
bRate per 100 person-years.
cAssociations with some evidence against the null.
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mutations in protease. The high genetic barrier of bPI to resist-
ance development could be a reason for this. It is worth noting 
that standard genotype tests based on pol sequencing ignore the 
influence of mutations in other genes such as gag [43–47] and 
env [48] on PI resistance. Notably, the individual with major pro-
tease resistance had received double-boosted PI treatment, and 
coupled with previous reports of multiple major protease resist-
ance mutations in children treated with double-dose PI [49, 50], 
further work regarding this approach is warranted.
The main methodological strength of this study is the appli-
cation of regression methods, which account for the presence 
of competing risks to estimate the rate of VF on second-line 
treatment and the association between covariates of interest and 
VF. Other cohort studies reporting outcomes on second-line 
treatment and factors associated with VF have used standard 
Kaplan-Meier survival analysis and Cox regression models, 
which can lead to biased or inflated estimates of association. As 
this analysis was done on prospectively collected data within a 
trial context with preset procedures rather than routine data, 
we also minimized the common problem of missing data and 
information bias.
There are some limitations of the study. First, although 
the sample size is small, the prevalence of VF on bPI we 
found is in line with other published studies. The inclusion 
of whole-genome sequencing data, albeit from 9 patients, is 
unique to this cohort. Second, the study was nested in a ran-
domized community trial and as such the patients may not 
be truly reflective of the general HIV population, given the 
intense monitoring and provision of counseling and adher-
ence interventions that may impact their attitude toward 
health and promote more successful treatment outcomes. 
We did not measure drug levels to assess pharmacokinetic 
drug–drug interactions or adherence before a clinical visit. 
Finally, 16 (15.8%) patients were included who were already 
on second-line ART at enrollment, for a median of 2.7 years, 
representing a potential bias.
There was also heterogeneity in the patient population. 
We included all participants from the parent study irrespec-
tive of study arm, though study arm had no effect on outcome, 
largely due to poor linkage to care in this setting (Dabis et  al, 
21st International AIDS Conference 2016, Durban, abstract 
FRAC0105LB). We included newly diagnosed as well as ART-
experienced patients, as both present for first-line therapy under 
“real-world” programmatic conditions, sometimes with evidence 
of drug resistance to thymidine analogues arising from prior 
ART [51] or with evidence of transmitted drug resistance [52].
In conclusion, this study found that second-line PI-based VF 
was common in this population accessing ART in rural South 
Africa under trial circumstances but recruited at the popula-
tion level. Further research is needed to understand the mech-
anisms behind VF of bPI ART in TB-coinfected patients. Novel 
approaches to optimize second-line ART in resource-limited 
settings are still urgently needed as this population is likely to 
grow rapidly, owing to the WHO 2015 guidelines to test and 
treat all people living with HIV [53].
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Natal, South Africa
 Delphine Perriat Epidemiology/social sciences - Univ. Bordeaux, ISPED, Centre Inserm U1219 Bordeaux 
Population Health, Bordeaux, France
- INSERM, ISPED, Centre Inserm U1219 Bordeaux Population 
Health, Bordeaux, France
 Melanie Plazy Epidemiology/social sciences - Univ. Bordeaux, ISPED, Centre Inserm U1219 Bordeaux 
Population Health, Bordeaux, France
- INSERM, ISPED, Centre Inserm U1219 Bordeaux Population 
Health, Bordeaux, France
 Camelia Protopopescu Statistics/Economist - INSERM, UMR912 (SESSTIM), Marseille, France
- Aix Marseille Université, UMR_S912, IRD, Marseille, France
- ORS PACA, Observatoire Régional de la Santé Provence- 
Alpes-Côte d’Azur, Marseille, France
 Luis Sagaon-Teyssier Health economics - INSERM, UMR912 (SESSTIM), Marseille, France
- Aix Marseille Université, UMR_S912, IRD, Marseille, France
- ORS PACA, Observatoire Régional de la Santé Provence- 
Alpes-Côte d’Azur, Marseille, France
 Bruno Spire Health economics - INSERM, UMR912 (SESSTIM), 13006, Marseille, France
- Aix Marseille Université, UMR_S912, IRD, Marseille, France
- ORS PACA, Observatoire Régional de la Santé Provence- 
Alpes-Côte d’Azur, Marseille, France
 Frank Tanser Epidemiology and Biostatistics - Africa Centre for Population Health, University of KwaZulu- 
Natal, South Africa
 Rodolphe Thiébaut Epidemiology and Biostatistics - Univ. Bordeaux, ISPED, Centre Inserm U1219 Bordeaux 
Population Health, Bordeaux, France
- INSERM, ISPED, Centre Inserm U1219 Bordeaux Population 
Health, Bordeaux, France
 Thierry Tiendrebeogo Epidemiology and Biostatistics - Univ. Bordeaux, ISPED, Centre Inserm U1219 Bordeaux 
Population Health, Bordeaux, France
- INSERM, ISPED, Centre Inserm U1219 Bordeaux Population 
Health, Bordeaux, France
 Thembelihle Zuma Psychology/Social sciences - Africa Centre for Population Health, University of KwaZulu- 
Natal, South Africa
Scientific advisory board
 Chair: Bernard Hirschel (Switzerland)
International experts
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 Xavier Anglaret (Ivory Coast)
 Hoosen Cooavdia (South Africa)
 Alpha Diallo (France)
 Bruno Giraudeau (France)
 Jean-Michel Molina (France)
 Lynn Morris (South Africa)
 François Venter (South Africa)
 Sibongile Zungu (South Africa)
Community representatives
 Eric Fleutelot (France)
 Eric Goemaere (South Africa)
 Calice Talom (Cameroon)
Sponsor representatives (ANRS)
 Brigitte Bazin
 Claire Rekacewicz
Pharmaceutical company representatives
 Golriz Pahlavan-Grumel (MSD)
 Alice Jacob (Gilead)
Data safety and monitoring board
 Chair: Patrick Yeni (France)
 Sinead Delany-Moretlwe (South Africa)
 Nathan Ford (South Africa)
 Catherine Hankins (Netherlands)
 Helen Weiss (UK)
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